GONZÁLEZ BREVIS, PABLO ENRIQUE
Thumbnail Image
Preferred name
GONZÁLEZ BREVIS, PABLO ENRIQUE
Official Name
González-Brevis, Pablo
Translated Name
González-Brevis, Pablo
Main Affiliation
Email
pablogonzalez@udd.cl
ORCID
Scopus Author ID
48361111600

Research Output

2024 2024 2023 2023 2022 2022 2021 2021 2020 2020 2019 2019 2018 2018 2017 2017 2016 2016 2015 2015 0.0 0.0 0.2 0.2 0.4 0.4 0.6 0.6 0.8 0.8 1.0 1.0

Filters
Reset filters

Settings
Now showing 1 - 3 of 3
No Thumbnail Available
Publication

A new warmstarting strategy for the primal-dual column generation method

2014 , Jacek Gondzio , GONZÁLEZ BREVIS, PABLO ENRIQUE

View
No Thumbnail Available
Publication

Large-scale optimization with the primal-dual column generation method

2015 , Jacek Gondzio , GONZÁLEZ BREVIS, PABLO ENRIQUE , Pedro Munari

View
No Thumbnail Available
Publication

Intravenous Thrombolysis in Patients 90 Years or Older with Moderate to Severe Acute Ischemic Stroke Increases Ambulation at Discharge and Is Safe: A Prospective Cohort Study from a Single Center in Santiago, Chile

2024 , GONZÁLEZ BREVIS, PABLO ENRIQUE , LAVADOS GERMAIN, PABLO MANUEL , André I. Aguirre , BRUNSER RABOVICH, ALEJANDRO MICHEL , OLAVARRIA IANISZEWSKY, VERONICA VIVIANA

<b><i>Introduction:</i></b> The World Health Organization predicts that the global population aged 60 years and older will double by 2050, leading to a significant rise in the public health impact of acute ischemic stroke (AIS). Existing stroke guidelines do not specify an upper age limit for the administration of intravenous thrombolysis (IVT), although some suggest a relative exclusion criterion in patients aged ≥80 in the 3–4.5-h window. Many physicians avoid treating these patients with IVT, argumenting high risk and little benefit. Our aim was to investigate the efficacy and safety of IVT treatment in patients with non-minor AIS aged ≥90, admitted to our institution. The primary efficacy endpoint was the ability to walk at discharge (mRS 0–3), and the primary safety endpoints were death and symptomatic intracranial hemorrhagic transformation (sIHT) at discharge. <b><i>Methods:</i></b> Patients with AIS aged ≥90 admitted to our center from January 2003 to December 2022 were included. They were selected if had an NIHSS ≥5, were previously ambulatory (prestroke mRS score 3 or less), and arrived within 6 h from symptom onset. Those treated or not with IVT were compared with univariate analysis. <b><i>Results:</i></b> The mean age was 93.2 (2.4) years, and 51 (73.9%) were female. The admission mRS and NIHSS were 1 (IQR 0–2) and 14 (IQR 7–22), respectively. Thrombolyzed patients had a shorter time from symptom onset to door and lower glycemia on admission. IVT was associated with a higher proportion of patients achieving mRS 0–3 at discharge (<i>p</i> = 0.03) and at 90 days (<i>p</i> = 0.04). There were no differences between groups in the risk of death (<i>p</i> = 0.55) or sIHT (<i>p</i> = 0.38). <b><i>Conclusion:</i></b> In this small sample, ambulatory patients aged ≥90 with moderate or severe AIS treated with IVT had increased odds of being able to walk independently at discharge than those not treated, without safety concerns.

View